+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 6Years - 11Years
All Genders
Healthy Volunteers
ID07567040

Evaluating Nightly 0.05% Atropine Eye Drops to Delay Nearsightedness Onset in Children Aged 6 to 11 Years

Led by Ohio State University · Updated on 2026-09-21

664

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether nightly use of 0.05% atropine eye drops can delay the onset of nearsightedness in children aged 6 to 11 years who are at high risk for developing myopia. This randomized clinical trial compares atropine drops with placebo drops given nightly in both eyes. The study aims to measure the two-year cumulative incidence of myopia and to determine if atropine slows eye growth compared to placebo. Participants receive either 0.05% atropine drops or placebo drops instilled in each eye every night at bedtime. The trial is conducted across multiple centers and includes 606 children randomized to one of the two groups. The study lasts at least two years, during which participants will be monitored to assess the onset of myopia and changes in eye growth. Throughout the trial, participants will have visits every six months for at least two years to evaluate eye measurements using devices like the Myopia Master. Researchers will track the development of myopia and axial elongation of the eye. Safety and adherence to the treatment will be monitored, and the primary outcomes focus on myopia incidence and eye growth over the two-year period.

CONDITIONS

Brief Title

Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial

Research Team

L

Lisa A Jordan, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here